BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

NCT01131676 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7064

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI 10773 low dose
DRUG: Placebo BI 10773 high dose
DRUG: BI 10773 high dose
DRUG: Placebo BI 10773 low dose
DRUG: Placebo BI 10773 low dose
DRUG: Placebo BI 10773 high dose

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]